In the past decade, capital investment in the field of CRISPR technology has seen a remarkable increase with a sharp increase starting in 2018 and persisting until 2021 with investments exceeded a staggering 11 billion USD in 2021 (Figure ). An overwhelming majority of these investments involved companies originating in the United States (USA, 96%). Other key players in terms of geographical distribution, though of much smaller magnitude, included Switzerland (CHE), China (CHN) and Japan (JPN) (Figure ).